Related Experiment Video

Updated: Feb 15, 2026

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

40.6K

Tolebrutinib and the FDA

Gavin Giovannoni1, Christopher H Hawkes1, Jeannette Lechner-Scott2

  • 1Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.

Multiple Sclerosis and Related Disorders
|February 13, 2026
PubMed
Summary

No abstract available in PubMed .

Keywords:
Bruton tyrosine kinase inhibitorsFood and drug administrationMultiple sclerosisParamagnetic rim lesionsSmouldering MSTolebrutinib

More Related Videos

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.6K
Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle05:05

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

Published on: November 4, 2011

21.7K

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
279